The shadow of generic competition has repeatedly loomed above copyright’s blockbuster drug, Sildenafil, raising questions about the future of connected pharmaceutical ventures. While first years saw significant returns, the patent end has created the way for cheaper copies, potentially diminishing profitability and presenting a significant danger